Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with glioblastoma (a type of brain tumour) for the first time, confirmed by laboratory testing of tissue
• People whose general health and ability to carry out daily activities meets a minimum functional score (called a Karnofsky Performance Score of 70% or above — confirm with trial site)
• People who have tested negative for HIV, Hepatitis B, and Hepatitis C, with specific blood test requirements depending on prior exposure history (confirm with trial site)
• Women who could become pregnant must have a negative pregnancy test within 14 days of starting treatment, and must agree to use highly effective contraception from the screening period until 6 months after the last dose of study treatment
• Men who could father children must agree to use two approved methods of contraception throughout the study
• People who have signed and dated a consent form showing they have been fully informed about the study
• People who are willing and able to attend scheduled visits, follow the treatment plan, and complete all required tests and procedures

Who may not be able to join:

• People who have already received treatment for their glioma, other than surgery
• People who are unable to have a contrast-enhanced MRI scan
• People who plan to use tumour-treating fields (a specific type of brain cancer therapy) before the disease gets worse
• People with a known allergy to the study drugs or any of their ingredients, or to any intravenously given human proteins, peptides, or antibodies
• People whose blood counts fall below specific minimum levels — including white blood cells, platelets, or haemoglobin (confirm exact values with trial site)
• People with long-term kidney function problems, based on specific blood test results (confirm with trial site)
• People with poor liver function, based on specific blood test results (confirm with trial site)
• People with blood clotting measurements above a certain level (confirm with trial site)
• People with any serious health condition that, in the treating doctor's opinion, would make participation unsafe or difficult
• People with an active autoimmune disease, or a history of one, that could get worse with immune-stimulating treatment
• People who have had a stroke or serious heart event (such as a heart attack or severe chest pain) within the past year
• People with moderate to severe heart failure (above Grade II on the NYHA scale — confirm with trial site)
• People with significant heart rhythm problems requiring ongoing medication
• People with certain abnormal heart test results, including a history of or current prolonged QT/QTc interval (a specific heart rhythm measurement)
• People with uncontrolled high blood pressure
• People with a known artery aneurysm at high risk of rupturing
• People with significant circulation problems in the limbs at a certain severity level (confirm with trial site)
• People with a documented history of, or currently experiencing, major depression, bipolar disorder, obsessive-compulsive disorder, schizophrenia, or who have a history of suicidal or homicidal thoughts or attempts, or who have severe personality disorders
• People experiencing significant anxiety at a certain severity level (Grade 3 or above — confirm with trial site)
• People with severe diabetic eye disease
• People who have had major surgery or serious physical trauma within the 3 weeks before starting study treatment
• People with a known history of tuberculosis
• People who are pregnant or breastfeeding
• People who require high-dose corticosteroids or other immune-suppressing medications on an ongoing basis (limited or occasional short-term use is generally not an exclusion — confirm with trial site)
• People with an active, uncontrolled infection or other serious illness that, in the treating doctor's opinion, would put them at undue risk
• People with another active cancer, unless they have been free of that cancer without any treatment for at least 2 years
• People who have received growth factors or immune-modifying agents within 7 days before starting study treatment
• People with a serious wound, ulcer, or bone fracture that is not healing
• People who require ongoing blood-thinning medication at treatment doses
• People who need other cancer treatments at the same time as the study treatment
• People who have received a live vaccine within 4 weeks before starting treatment, or who plan to receive one during the study

Important: Always verify eligibility with the trial site directly before applying.